Sep 2026· European journal of paediatric neurology· Vol 65, pp.
15-20
· 0 citations· 41 references
Medicine
TL;DR
POMS is rare in Finland, and although ON was seen in 32% of all cases of CIS, other mono- and multifocal manifestations predominated in those who developed POMS.
Abstract
INTRODUCTION
Although there are extensive data on multiple sclerosis (MS) in adults, the epidemiology and clinical features of pediatric-onset multiple sclerosis (POMS) in Finland are unknown.
SUBJECTS
and methods: Individuals under 18 years of age diagnosed with clinically isolated syndrome (CIS) or MS were identified from the MS registries of Tampere and Helsinki University Hospitals, based on the ICD-10 classification. The data were extracted from the electronic patient records (EPRs) and MS registries.
Results
A total of 73 children with CIS were identified. Among these, 34 (47%) were diagnosed with MS before the age of 18, and an additional 8 (11%) by the age of 28. The median time from CIS to a diagnosis of MS in those diagnosed before 18 was 6 months. CIS phenotypes included optic neuritis (ON) in 23/73 (32%), acute disseminated encephalomyelitis (ADEM) in 10/73 (14%), transverse myelitis (TM) in 9/73 (12%), internuclear ophthalmoplegia (INO) in 5/73 (7%) and other or undefined monofocal presentations in 15/73 (21%) and multifocal presentations in 11/73 (15%). The prevalence of POMS in our cohort was 5.5 per 100,000, with an incidence ranging from 0.16 to 0.81 per 100,000.
Conclusion
POMS is rare in Finland. Although ON was seen in 32% of all cases of CIS, other mono- and multifocal manifestations predominated in those who developed POMS. Unlike in adults, ADEM can also rarely develop into MS in pediatric patients.
Patients with LOMS tend to have a higher prevalence of PPMS, a greater burden of comorbidities, higher baseline disability, lower relapse activity, and a shorter time to CDP.
A. Fouad, Abdallah Saad, Hadeer Mohamed Abd El-Aziz et al.· Multiple Sclerosis and Relat...· 0 citations
Background: Age at multiple sclerosis (MS) diagnosis may be associated with clinical course, inflammatory activity, and disability accrual, but evidence across the full age spectrum remains limited. We compared clinical and radiological features, phenotype distribution, and time to first post-diagnosis relapse across e...
O. Mirmosayyeb, Sepehr Aghajanian, Fatemeh Mohammadifard et al.· The Neuroscientist· 0 citations
This review summarizes the diagnostic work-up of children with a first acquired demyelinating syndrome, differential diagnosis, the role of MRI, cerebrospinal fluid (CSF) markers, antibody testing, serum neurofilament light chain, optical pathway assessment and the 2024 McDonald criteria.
M. Margoni, Massimo Filippi, M. Rocca· Expert Review of Neurotherap...· 0 citations
OBJECTIVE
Despite representing the most common and fastest growing form of epilepsy in older adults, the clinical features of late onset epilepsy (LOE) and how it differs from early onset epilepsy (EOE) remain largely underexplored. Therefore, we evaluate the characteristics and risk factors of LOE compared to EOE.
M...
Syeda Amrah Hashmi, Mark Quigg, M. Abbas et al.· Epilepsia· 0 citations
The Gulf POMS evidence base is real but narrow, concentrated, and heterogeneous; a scoping review is currently the more informative synthesis than a quantitative meta-analysis, which supports a harmonized, multi-country Gulf pediatric MS registry with standardized outcome reporting, including neurocognitive and quality...
E. Shosha, N. Qadi, Rakan S. Alromayan et al.· Biomedicines· 0 citations